Global Lynch Syndrome Market, By Treatment (Colonoscopy, Upper Endoscopy, Chemotherapy, Radiation Therapy, Genetic Counselling, Orphan Drugs, Aspirin, Others), Diagnosis (Genetic Testing, Tumour Testing, Others), Dosage (Injection, Tablets, Others), Route of Administration (Oral, Intravenous, Others), Symptoms (Bowel Habits, Blood in Faeces, Abdominal Pain Bloating, Weight Loss, Anaemia, Fatigue, Constipation, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2030.
Lynch Syndrome Market Analysis and Size
The rise in the prevalence of cancer will act as major driver that will results in the expansion of market’s growth. Another significant factor influencing the growth rate of global lynch syndrome market is the rising healthcare expenditure. Furthermore, advancement in the medical technology, rising initiatives by public and private organisations to spread awareness and growing government funding are the factors that will expand the global lynch syndrome market. Other factors such as increase in the demand for effective therapies and rising geriatric population will positively impact the global lynch syndrome market growth rate. Additionally, high disposable income and changing lifestyle will result in the expansion of global lynch syndrome market. Also, growing adoption rate of early genetic counselling will enhance the growth of global lynch syndrome market.
Data Bridge Market Research analyses that the global lynch syndrome market which was USD 1552 million in 2022, is expected to reach USD 2437.79 million by 2030, and is expected to undergo a CAGR of 5.8% during the forecast period 2023-2030. This indicates that the market value. “Hospital” dominates the end user segment of the global lynch syndrome market due to rising awareness of proper treatment. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Lynch Syndrome Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Products (Electrosurgical Instruments, Electrosurgical Generators, Plasma and Smoke Management Systems, Electrosurgical Accessories), Surgery (Gynaecological Surgery, Urology Surgery, Cardiovascular Surgery, General Surgery, Neurosurgery, Orthopaedic Surgery, Cosmetic Surgery, Others), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centres, Others), Distribution Channel (Direct, Retail)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of the Middle East & Africa
|
|
Market Players Covered
|
Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Bristol-Myers Squibb Company (U.S.), Bayer AG (Germany),DAIICHI SANKYO COMPANY, LIMITED (Japan), GlaxoSmithKline plc (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Amgen Inc. (U.S.), AbbVie Inc. (U.S.), Eli Lilly and Company (U.S.), Astellas Pharma Inc. (Japan), Eisai Co. (Japan), Merck & Co., Inc. (U.S.), Gilead Sciences, Inc. (U.S.), Alexion Pharmaceuticals, Inc. (U.S.), Vertex Pharmaceuticals Incorporated (U.S.), Boehringer Ingelheim International GmbH (Germany), Janssen Global Services, LLC (Belgium) - A subsidiary of Johnson & Johnson, Biogen (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Lynch syndrome is an inherited cancer syndrome that is linked to a genetic propensity to various cancers. This indicates that persons with Lynch syndrome are more likely to get specific cancers. Lynch syndrome is one of the most frequent hereditary cancer syndromes, with estimates indicating that 1 in every 300 persons may carry a gene mutation linked to lynch syndrome. This condition is also termed as hereditary non-polyposis colorectal cancer (HNPCC). Signs and symptoms of Lynch syndrome involve changes in bowel habits, blood in faeces, abdominal pain and bloating, weight loss, anaemia, fatigue, and constipation, among others. It has an autosomal dominant pattern of inheritance and occurs due to changes in MLH1, MSH2, MSH6, PMS2 or EPCAM gene.
Global Lynch Syndrome Market Dynamics
Drivers
- Increasing Awareness and Genetic Testing
Growing awareness about Lynch Syndrome, coupled with advancements in genetic testing technologies, has led to increased screening rates. Early diagnosis is crucial, driving the demand for genetic testing services and creating market growth.
- Rising Cancer Incidence Rates
The overall increase in cancer incidence rates, especially colorectal and endometrial cancers, has intensified the focus on genetic screening for Lynch Syndrome, fostering market growth..
- Advancements in Genomic Medicine
Technological advancements, such as next-generation sequencing and precision medicine, have improved the accuracy and accessibility of genetic testing, facilitating early diagnosis and personalized treatment plans.
Opportunities
- Personalized Medicine and Targeted Therapies
Advancements in understanding Lynch Syndrome genetics create opportunities for the development of targeted therapies and personalized treatment approaches, enhancing the overall management of patients with Lynch Syndrome.
- Genetic Counselling Services
Increasing demand for genetic counselling services presents opportunities for healthcare providers and genetic testing companies to offer comprehensive support, education, and guidance to individuals and families affected by Lynch Syndrome.
Restraints/ Challenges
- Limited Awareness in Certain Regions
Limited awareness and lack of education about Lynch Syndrome in certain regions can hinder early diagnosis and screening efforts, restraining market growth in these areas.
- Ethical and Privacy Concerns
Genetic testing raises ethical concerns related to privacy, consent, and potential discrimination. Addressing these concerns and ensuring stringent data protection measures is crucial to gaining patient trust and market acceptance.
- Interpretation of Genetic Variants
Lynch Syndrome involves numerous genetic variants, and interpreting these variants accurately can be challenging. Standardizing interpretation protocols and continuous research are necessary to ensure reliable results.
- Patient Compliance and Follow-Up
Ensuring patient compliance with regular screenings and follow-up appointments is challenging. Patient education and awareness campaigns are essential to encourage ongoing monitoring and management.
This global lynch syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global lynch syndrome market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Lynch Syndrome Market Scope
The global lynch syndrome market is segmented on the basis of treatment, diagnosis, dosage, route of administration, symptoms, end-users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
Treatment
- Colonoscopy
- Upper endoscopy
- Chemotherapy
- Radiation therapy
- Genetic counseling
- Orphan drugs
- Aspirin
- Others
Diagnosis
- Genetic Testing
- Tumour Testing
- Others
Dosage
- Injection
- Tablets
- Others
Route of Administration
- Oral
- Intravenous
- Others
Symptoms
- Changes in Bowel Habits
- Blood in Faeces
- Abdominal pain and Bloating
- Weight Loss
- Anaemia
- Fatigue
- Constipation
- Others
End-User
- Clinic
- Hospital
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Lynch Syndrome Market Regional Analysis/Insights
The global lynch syndrome market is analysed and market size insights and trends are provided by country, treatment, diagnosis, dosage, route of administration, symptoms, end-users and distribution channel as referenced above.
The countries covered in the global lynch syndrome market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the global lynch syndrome market due to the presence of major key players, high disposable income and well-developed healthcare infrastructure in this region.
Asia-Pacific is expected to show a rapid and lucrative growth rate in the forecast period of 2023 to 2030 due to the increasing patient pool, rising investment in the healthcare sector and growing government support.
The country section of the global lynch syndrome market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. The global lynch syndrome market is analysed and market size insights and trends are provided by country, product, indication and end user as referenced above.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global lynch syndrome market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global lynch syndrome market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on global lynch syndrome market. The data is available for historic period 2015-2020.
Competitive Landscape and Global Lynch Syndrome Market Share Analysis
The global lynch syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global lynch syndrome market.
Some of the major players operating in the global lynch syndrome market are:
- Novartis AG (Switzerland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Bayer AG (Germany)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
- GlaxoSmithKline plc (U.K.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Amgen Inc. (U.S.)
- AbbVie Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- Astellas Pharma Inc. (Japan)
- Eisai Co. (Japan)
- Merck & Co., Inc. (U.S.)
- Gilead Sciences, Inc. (U.S.)
- Alexion Pharmaceuticals, Inc. (U.S.)
- Vertex Pharmaceuticals Incorporated (U.S.)
- Boehringer Ingelheim International GmbH (Germany)
- Janssen Global Services, LLC (Belgium) - A subsidiary of Johnson & Johnson
- Biogen (U.S.)
SKU-